clinical trial · NCT07378527
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Beijing InnoCare Pharma Tech Co., Ltd.·phase3·recruiting·n = 344
Chronic Spontaneous Urticaria (CSU)ICP-332 TabletsICP-332 placebo TabletsICP-332 Tablets
brief summary
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
started
Feb 13, 2026
primary completion
Sep 1, 2028
completion
Sep 1, 2028
last updated
Apr 21, 2026
official title
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Moderate to Severe Chronic Spontaneous Urticaria Subjects Inadequately Controlled by Second Generation H1-antihistamines
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol